Swiss drugmaker Roche has announced that the phase III clinical trial for its blood cancer drug did not meet its endpoint. The drug is designed to treat an aggressive form of blood cancer known as diffuse large B-cell lymphoma.
Swiss drugmaker Roche has announced that the phase III clinical trial for its blood cancer drug did not meet its endpoint. The drug is designed to treat an aggressive form of blood cancer known as diffuse large B-cell lymphoma.
Share this Article
Recommended